Related Experiment Video
Updated: Jan 28, 2026

Genome Editing in Astyanax mexicanus Using Transcription Activator-like Effector Nucleases TALENs
Published on: June 20, 2016
Genome Editing with mRNA Encoding ZFN, TALEN, and Cas9
Hong-Xia Zhang1, Ying Zhang2, Hao Yin1
1Department of Urology, Zhongnan Hospital of Wuhan University, 430071 Wuhan, China; Medical Research Institute, Wuhan University, 430071 Wuhan, China.
Abstract:
Genome-editing technologies based on programmable nucleases have significantly broadened our ability to make precise and direct changes in the genomic DNA of various species, including human cells. Delivery of programmable nucleases into the target tissue or cell is one of the pressing challenges in transforming the technology into medicine. In vitro-transcribed (IVT) mRNA-mediated delivery of nucleases has several advantages, such as transient expression with efficient in vivo and in vitro delivery, no genomic integration, a potentially low off-target rate, and high editing efficiency. This review focuses on key barriers related to IVT mRNA delivery, on developed modes of delivery, and on the application and future prospects of mRNA encoding nuclease-mediated genome editing in research and clinical trials.
Related Concept Videos
CRISPR/Cas9 Genome Editing
RNA Editing
mRNA Stability and Gene Expression
Cis-acting Elements involved in mRNA stability
Regulated mRNA Transport
pre-mRNA Processing
Once about 20-40 ribonucleotides have been joined together by RNA polymerase, a group of enzymes adds a “cap” to the 5’ end of the growing transcript. In this process, a 5’ phosphate is replaced by modified guanosine that has a methyl group attached to it (7-Methyl...
Nuclear Export of mRNA

